Literature DB >> 28487112

Editor's Choice - Outcomes of Self Expanding PTFE Covered Stent Versus Bare Metal Stent for Chronic Iliac Artery Occlusion in Matched Cohorts Using Propensity Score Modelling.

M Piazza1, F Squizzato2, A Dall'Antonia2, S Lepidi2, M Menegolo2, F Grego2, M Antonello2.   

Abstract

OBJECTIVES: The aim was to compare outcomes of self expanding PTFE covered stents (CSs) with bare metal stents (BMSs) in the treatment of iliac artery occlusions (IAOs).
METHODS: Between January 2009 and December 2015, 128 iliac arteries were stented for IAO. A CS was implanted in 78 iliac arteries (61%) and a BMS in 50 (49%). After propensity score matching, 94 limbs were selected and underwent stenting (47 for each group). Thirty day outcomes and midterm patency were compared; follow-up results were analysed with Kaplan-Meier curves.
RESULTS: Overall, iliac lesions were classified by limb as TASC B (19%), C (21%), and D (60%). Technical success was 98%. Comparing CS versus BMS, the early cumulative surgical complication rate (12% vs. 12%, p = 1.0) and 30 day mortality rate (2% vs. 2%, p = 1.0) were equivalent. At 36 months (average 23 ± 17), overall primary patency was similar between CS and BMS (87% vs. 66%, p = .06), and this finding was maintained after stratification by TASC B (p = .29) and C (p = .27), but for TASC D, CSs demonstrated a higher patency rate (CS, 88% vs. BMS, 54%; p = .03). In particular, patency was in favour of CSs for IAOs > 3.5 cm in length (p = .04), total lesion length > 6 cm (p = .04), and IAO with calcification > 75% of the arterial wall circumference (p = .01).
CONCLUSIONS: Overall, the use of self expanding CS for IAOs has similar early and midterm outcomes compared with BMS. Even if further confirmatory studies are needed, CSs seem to have higher midterm patency rates than BMSs for TASC D lesions, IAOs with a total lesion length > 6 cm, occlusion length > 3.5 cm, and calcification involving > 75% of the arterial wall circumference. These specific anatomical parameters may be useful to the operator when deciding between CS and BMS during endovascular planning.
Copyright © 2017 European Society for Vascular Surgery. Published by Elsevier Ltd. All rights reserved.

Entities:  

Keywords:  Hybrid procedure; Iliac artery occlusion; Iliac stenting; Peripheral artery disease; Stent

Mesh:

Substances:

Year:  2017        PMID: 28487112     DOI: 10.1016/j.ejvs.2017.03.019

Source DB:  PubMed          Journal:  Eur J Vasc Endovasc Surg        ISSN: 1078-5884            Impact factor:   7.069


  5 in total

1.  SCAI guidelines on device selection in Aorto-Iliac arterial interventions.

Authors:  Dmitriy N Feldman; Ehrin J Armstrong; Herbert D Aronow; Subhash Banerjee; Larry J Díaz-Sandoval; Michael R Jaff; Sasanka Jayasuriya; Safi U Khan; Andrew J Klein; Sahil A Parikh; Kenneth Rosenfield; Mehdi H Shishehbor; Rajesh V Swaminathan; Christopher J White
Journal:  Catheter Cardiovasc Interv       Date:  2020-05-14       Impact factor: 2.692

2.  Comparison of BARD®LIFESTREAM™ covered balloon-expandable stent versus GORE® VIABAHN™ covered self-expandable stent in treatment of aortoiliac obstructive disease: study protocol for a prospective randomized controlled trial (NEONATAL trial).

Authors:  Yuhan Qi; Jiarong Wang; Jichun Zhao; Bing Huang; Fei Xiong; Xiaojiong Du; Xiyang Chen; Qiang Guo; Tiehao Wang; Ding Yuan
Journal:  Trials       Date:  2022-05-12       Impact factor: 2.728

Review 3.  [Recommended interventions for the treatment of peripheral artery disease : Keep the patients moving].

Authors:  H Krankenberg
Journal:  Internist (Berl)       Date:  2019-12       Impact factor: 0.743

Review 4.  [Endovascular Revascularization for Aortoiliac Occlusive Disease].

Authors:  Myungsu Lee
Journal:  Taehan Yongsang Uihakhoe Chi       Date:  2021-05-28

5.  Midterm outcomes of endovascular treatment with bare metal stents for Leriche syndrome patients.

Authors:  Bihui Zhang; Guochen Niu; Ziguang Yan; Yinghua Zou; Xiaoqiang Tong; Min Yang
Journal:  Interact Cardiovasc Thorac Surg       Date:  2021-01-01
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.